Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.

Surgical pathology clinics - 1 Mar 2022

Jagannathan Geetha, White Marissa J, Xian Rena R, Emens Leisha A, Cimino-Mathews Ashley

Abstract excerpt

Predictive biomarker testing on metastatic breast cancer is essential for determining patient eligibility for targeted therapeutics. The National Comprehensive Cancer Network currently recommends assessment of specific biomarkers on metastatic tumor subtypes, including hormone receptors, HER2, and BRCA1/2 mutations, on all newly metastatic breast cancers subtypes; programmed death-ligand 1 on metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to Carcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 35236627
DOI: 10.1016/j.path.2021.11.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.PMID 35236627Read ↗

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.Semantic proximity Read ↗

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.Semantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Semantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.Semantic proximity Read ↗

New Views into the Genetic Landscape of Metastatic Breast Cancer.Semantic proximity Read ↗

The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors.Semantic proximity Read ↗

Clinical implications of prospective genomic profiling of metastatic breast cancer patients.Semantic proximity Read ↗

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasisSemantic proximity Read ↗

Current and Emerging Biomarkers in Metastatic Colorectal CancerSemantic proximity Read ↗

Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.